Cytokinetics(US:CYTK) Newsfile·2025-11-12 00:57Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated related to misleading statements about the New Drug Application (NDA) for aficamten, with a lead plaintiff deadline of November 17, 2025 [2][5]. Group 1: Legal Investigation - The law firm is reminding investors of the upcoming deadline to seek the role of lead plaintiff in a federal securities class action against Cytokinetics [2]. - Investors who acquired Cytokinetics securities between December 27, 2023, and May 6, 2025, are encouraged to discuss their legal rights [1][2]. Group 2: Allegations Against Cytokinetics - The complaint alleges that Cytokinetics made materially false and misleading statements regarding the NDA submission timeline and approval process for aficamten, claiming expected FDA approval in the second half of 2025 [5]. - It was revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [6]. Group 3: Impact on Investors - As a result of the misleading statements, investors purchased Cytokinetics' common stock at inflated prices and suffered significant losses when the truth was disclosed [7]. - The lead plaintiff in the class action will be the investor with the largest financial interest who can adequately represent the class [8].